biostudies-literatureUnknown6(6)Yang HThe non-germinal center B-cell like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK) inhibitors have established therapeutic activity in B-cell malignancies, with modest activity in DLBCL. Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in patients with relapsed or refractory (R/R) non-GCB DLBCL. The BGB-3111-207 study (NCT03145064) was a multicenter single-arm phase 2 study. Patients received twice-daily oral zanubrutinib, 160 mg, until disease progression or unacceptable toxicity. The primary end point was the overall response rate (ORR). Secondary end points included progression-free survival (PFS) and duration of response (DOR). Overall survival (OS) was an exploratory end point. Forty-one patients werBlood advances1629-1636https://www.ebi.ac.uk/biostudies/studies/S-EPMC8941452biostudies-literatureZanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.PMC8941452Yang HLi CHuang JZhang HGuo WNovotny WZhao WZou DXiang BLiu YLi YLv FTan ZGuo HLiu AFu LSong YfalseZanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.The non-germinal center B-cell like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK) inhibitors have established therapeutic activity in B-cell malignancies, with modest activity in DLBCL. Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in patients with relapsed or refractory (R/R) non-GCB DLBCL. The BGB-3111-207 study (NCT03145064) was a multicenter single-arm phase 2 study. Patients received twice-daily oral zanubrutinib, 160 mg, until disease progression or unacceptable toxicity. The primary end point was the overall response rate (ORR). Secondary end points included progression-free survival (PFS) and duration of response (DOR). Overall survival (OS) was an exploratory end point. Forty-one patients wer2022-01-01T00:00:00Z2022 Mar2026-05-10T01:38:13.961Z2025-02-19T01:11:53.492ZS-EPMC89414523463813610.1182/bloodadvances.2020003698